Financials in USD. Standardized financial statements.
A compact view of how AzurRx BioPharma, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $36,251 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin? | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $6.43M | $15.62M | $26.43M | $14.74M | $13.43M | $10.08M | $6.63M | -$3.33M |
| Operating Income? | -$7.08M | -$15.62M | -$26.43M | -$14.74M | -$13.43M | -$10.08M | -$6.63M | -$4.73M |
| EBITDA? | -$7.08M | -$15.62M | -$26.83M | -$13.72M | -$12.63M | -$9.47M | -$7.92M | -$3.61M |
| Income Before Tax | -$6.55M | -$18.06M | -$32.67M | -$15.18M | -$13.53M | -$11.10M | -$14.59M | -$5.93M |
| Income Tax Expense | $0 | $0 | -$398,084 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$6.55M | -$18.06M | -$32.67M | -$15.18M | -$13.53M | -$11.10M | -$14.59M | -$5.93M |
| EPS? | $-4.16 | $-5.33 | $-5.90 | $-6.77 | $-8.77 | $-10.44 | $-14.96 | $-6.16 |
| Diluted EPS? | $-4.16 | $-5.33 | $-5.90 | $-6.77 | $-8.77 | $-10.44 | $-22.43 | $-6.16 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality